^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XY0206

    i
    Other names: XY0206
    Company:
    Shijiazhuang Yiling Pharma
    Drug class:
    FLT3 inhibitor
    Related drugs:
    1year
    A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (ASH 2023)
    XY0206 is a novel FLT3 inhibitor that showed a good safety profile, a potent anti-leukemic activity and improved efficacy in patients with FLT3mut+ R/R AML.
    Clinical • P1/2 data
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 positive
    |
    XY0206
    over1year
    A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) (clinicaltrials.gov)
    P3, N=312, Not yet recruiting, Shijiazhuang Yiling Pharmaceutical Co. Ltd
    New P3 trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation
    |
    cytarabine • azacitidine • XY0206
    over1year
    A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=60, Recruiting, Shijiazhuang Yiling Pharmaceutical Co. Ltd | Trial completion date: Dec 2022 --> Feb 2024 | Trial primary completion date: Jul 2022 --> Feb 2024
    Trial completion date • Trial primary completion date
    |
    XY0206
    4years
    A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=34, Recruiting, Shijiazhuang Yiling Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    KDR (Kinase insert domain receptor)
    |
    XY0206